The fund employs fundamental analysis focusing on current or anticipated market position, experienced business management, recognized technological expertise, and ability to generate or secure capital for growth. abrdn Healthcare Investors offers a discounted entry into the healthcare sector, with a strong tilt toward biotechnology exposure and active management.
Cyborg Score Rationale
HQH stock has gained 30.8% over the past year. The fund offers a high dividend yield of 13.6%, making it attractive for income-focused investors. However, the fund has been downgraded due to persistent underperformance and heavy concentration in biotechnology.
Top Insights
Market cap of approximately $1.1B as of April 2026.
30.8% gain over the past 12 months through April 2026.
The fund trades at a 7.86% discount to NAV, presenting a potentially attractive entry point.
Healthcare is positioned for a higher 2026 distribution as healthcare demand remains a powerful force.
Named Competitors
CHY — Convertible and high income closed-end fund
EMO — Energy midstream focused closed-end fund
AOD — Dynamic dividend closed-end fund
NRK — Municipal bond closed-end fund
Recent Developments
(February 2026) Aberdeen Investments U.S. Closed-End Funds portfolio announcement
(April 2026) Recent SEC filings including Form 3 and Form DEF 14A
(May 2026) Trading at approximately $17.79-$19.88 per share with high liquidity indicators
Open the full interactive abrdn Healthcare Investors report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.